Verrica Pharmaceuticals
Stock Forecast, Prediction & Price Target
Verrica Pharmaceuticals Financial Estimates
Verrica Pharmaceuticals Revenue Estimates
Verrica Pharmaceuticals EBITDA Estimates
Verrica Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $12M N/A | $9.03M -24.73% | $5.12M -43.26% | Avg: $72.08M Low: $56.93M High: $84.20M avg. 1306.85% | Avg: $155.21M Low: $122.95M High: $188.66M avg. 115.31% | Avg: $216.58M Low: $171.56M High: $263.25M avg. 39.53% | Avg: $279.59M Low: $221.48M High: $339.84M avg. 29.09% |
Net Income
% change YoY
| $-38.90M N/A | $-27.67M 28.85% | $-66.99M -142.05% | Avg: $-42.84M Low: $-63.02M High: $-20.40M avg. 36.05% | Avg: $21.07M Low: $-16.77M High: $74.81M avg. 149.20% | Avg: $21.46M Low: $15.66M High: $27.47M avg. 1.81% | Avg: $56.98M Low: $41.58M High: $72.94M avg. 165.49% |
EBITDA
% change YoY
| $-30.78M N/A | $-20.87M 32.18% | $-62.19M -197.90% | Avg: $-14.41M Low: $-16.84M High: $-11.38M avg. 76.81% | Avg: $-31.04M Low: $-37.73M High: $-24.59M avg. -115.31% | Avg: $-43.31M Low: $-52.65M High: $-34.31M avg. -39.53% | Avg: $-55.91M Low: $-67.96M High: $-44.29M avg. -29.09% |
EPS
% change YoY
| -$1.44 N/A | -$0.81 43.74% | -$1.48 -82.71% | Avg: -$0.81 Low: -$1.39 High: -$0.45 avg. 45.40% | Avg: $0.44 Low: -$0.37 High: $1.65 avg. 153.83% | Avg: $0.47 Low: $0.35 High: $0.61 avg. 8.81% | Avg: $1.26 Low: $0.92 High: $1.61 avg. 165.49% |
Operating Expenses
% change YoY
| $42.90M N/A | $29.60M -31.00% | $70.13M 136.92% | Avg: $220.95M Low: $174.52M High: $258.09M avg. 215.03% | Avg: $475.75M Low: $376.87M High: $578.27M avg. 115.31% | Avg: $663.85M Low: $525.88M High: $806.91M avg. 39.53% | Avg: $856.98M Low: $678.87M High: $1.04B avg. 29.09% |
FAQ
What is Verrica Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 88.14% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -63.02M, average is -42.84M and high is -20.40M.
What is Verrica Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 372.69% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $56.93M, average is $72.08M and high is $84.20M.
What is Verrica Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 93.38% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.39, average is -$0.81 and high is $-0.45.
What is the best performing analyst?
In the last twelve months analysts have been covering Verrica Pharmaceuticals stock. The most successful analyst is Oren Livnat.